Health

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

Tuesday, October 15, 2019 - 7:00am

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.

Key Points: 
  • LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.
  • Kathleen Rickard, M.D., CMO at Verona Pharma, will expand on symptom data first announced by the Company on March 26, 2018 where ensifentrine produced clinically and statistically significant improvements in lung function as well as significant and progressive improvements in COPD symptoms.
  • Oral Presentation/Poster: Poster E1037 Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
    COPD is a progressive and life-threatening respiratory disease without a cure.
  • Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharmas prior Phase 2 clinical studies in patients with moderate-to-severe COPD.

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Tuesday, October 15, 2019 - 7:45am

Takeda remains committed to this region, as we continue our work in accelerating access to our life-changing portfolio of innovative products to meet the needs of patients.

Key Points: 
  • Takeda remains committed to this region, as we continue our work in accelerating access to our life-changing portfolio of innovative products to meet the needs of patients.
  • We will do this via our commercial activities and Takedas Access to Medicines program, said Ricardo Marek, President, Growth and Emerging Markets Business Unit, Takeda.
  • "We are confident that Acino is best positioned to provide uninterrupted access and supply of the divested products to patients.
  • Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying its portfolio.

Potential Link Between Heart Disease and Tooth Loss Highlights Need for Good Oral Healthcare, says Beverly Hills Periodontics and Dental Implant Center

Tuesday, October 15, 2019 - 7:00am

Beverly Hills Periodontics & Dental Implant Center says that this growing evidence adds real urgency to the importance of treating periodontal problems and preventing tooth loss, as well as replacing any missing teeth with dental implants whenever possible.

Key Points: 
  • Beverly Hills Periodontics & Dental Implant Center says that this growing evidence adds real urgency to the importance of treating periodontal problems and preventing tooth loss, as well as replacing any missing teeth with dental implants whenever possible.
  • The oral care center says that both moderate and severe cases of gum diseases often cause severe inflammation, halitosis (bad breath), receding gums, and bone loss.
  • Beverly Hills Periodontics & Dental Implant Center notes that many patients tend to put off oral healthcare, which can only make matters more dangerous and painful.
  • Interested readers can find out more about Beverly Hills Periodontics and Dental Implant Center by visiting the clinic's website at https://www.bhperiodontist.com/ or by calling (310) 275-4606.

First Algenex CrisBio®-based vaccine submitted to European Medicines Agency

Tuesday, October 15, 2019 - 7:00am

Madrid (Spain), October 15, 2019 Algenex SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, today announces that one of its industry partners has submitted a dossier to the European Medicines Agency (EMA) for a recombinant VLP vaccine produced using Algenex proprietary CrisBio technology.

Key Points: 
  • Madrid (Spain), October 15, 2019 Algenex SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, today announces that one of its industry partners has submitted a dossier to the European Medicines Agency (EMA) for a recombinant VLP vaccine produced using Algenex proprietary CrisBio technology.
  • The submission is targeting a European marketing authorization via the centralized approval system.
  • This is the first vaccine produced using Algenex CrisBio technology to be submitted for regulatory approval.
  • CrisBio is Algenex proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors.

FDAnews Announces -- Labeling for Prescription Drugs, Biologics and Combination Products:Complying with FDA's Most Recent IFU Guidance Webinar, Oct. 29, 2019

Tuesday, October 15, 2019 - 5:00am

What implications does the recent Instructions for Use (IFU) guidance have on new drug applications and biologics license applications?

Key Points: 
  • What implications does the recent Instructions for Use (IFU) guidance have on new drug applications and biologics license applications?
  • How will the current content and format for IFUs need to be modified?
  • a partner and leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP will clarify the new guidance and explain how to comply with it.
  • Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
    to learn about our special multisite discount.

MPIC Raises Php 35.3bn from KKR’s Investment in Hospital Unit

Tuesday, October 15, 2019 - 1:43am

GIC will restructure its current investment in Metro Pacific Hospitals and will re-invest alongside KKR.

Key Points: 
  • GIC will restructure its current investment in Metro Pacific Hospitals and will re-invest alongside KKR.
  • As part of MPIC's wider financing arrangements, the KKR-led consortium will also invest in a Php 30.1 billion (US$ 580.0 million) mandatorily exchangeable bond issued by MPIC.
  • MPIC plans to use the proceeds of this issuance to reduce its bank borrowings.
  • KKR's record of assisting transformational businesses is well known, and our plans for the future of Metro Pacific Hospitals are ambitious."

BioMed Realty Announces 300,000 Square Feet Long-term Lease at Emeryville Center of Innovation Campus

Tuesday, October 15, 2019 - 12:48am

BioMed Realty, a leading provider of real estate solutions for the life science industry, announced today that it has executed a 12-year lease with Zymergen for 300,000 square feet at Emeryville Center of Innovation.

Key Points: 
  • BioMed Realty, a leading provider of real estate solutions for the life science industry, announced today that it has executed a 12-year lease with Zymergen for 300,000 square feet at Emeryville Center of Innovation.
  • BioMed Realty will invest capital to transform the existing asset into a dynamic and innovative Class A environment for Zymergens new headquarters location.
  • Zymergen is a leading science and material innovation company and one of the largest employers in Emeryville.
  • We are thrilled to welcome the team at Zymergen to their new home at the Emeryville Center of Innovation, said Denis Sullivan, EVP and Chief Investment Officer of BioMed Realty.

National University Advances Support of Workforce Development Through Partnership with American Medical Response

Tuesday, October 15, 2019 - 12:18am

National University will be renamed Sanford National University in honor of Mr. Sanfords vision and generosity effective July 1, 2020.

Key Points: 
  • National University will be renamed Sanford National University in honor of Mr. Sanfords vision and generosity effective July 1, 2020.
  • Through this partnership with American Medical Response, the National University System is expanding our vision of ensuring that our workforce needs are met through access to a quality, affordable degree, said Dr. Michael R. Cunningham, Chancellor of the National University System.
  • Exploring new ways to assess prior training and education, which includes identifying competency-based and prior-learning approaches, is part of a larger industry partnership and scholarship initiative by the National University System, which includes National University, City University of Seattle, John F. Kennedy and Northcentral University.
  • NUS higher-education institutions serve more than 45,000 students through National University, Northcentral University, City University of Seattle, and John F. Kennedy University.

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Lords committee question Chief Medical Officer and academics about healthy life expectancy

Tuesday, October 15, 2019 - 12:01am

The Committee questions the Chief Medical Officer for England, Professor Chris Whitty, and academic experts.

Key Points: 
  • The Committee questions the Chief Medical Officer for England, Professor Chris Whitty, and academic experts.
  • In the first session, the Committee explores with the Chief Medical Officer for England the extent to which factors such as location, gender, ethnicity and wealth affect healthy life expectancy, and what the current UK priorities are to improve health span.
  • How effective is public health advice for healthy ageing, and can it be updated based on any recent research?
  • What are the main conditions or diseases, covering physical and mental health, that affect older people in the cohorts?